We combine extensive physiological examinations of cohorts of healthy individuals and patients with well-defined metabolic dysfunctions with omics-based analyses of a variety of biological samples from the study participants.

The omics approaches include metagenomics, metabolomics, proteomics and genomics. The generated data are bioinformatically analysed and integrated. We test the relevance and validity of the outcome experimentally in molecular-, cellular- and animal studies and in human interventions.

Human gut microbes impact host serum metabolome and insulin sensitivity 
The study points to the role of specific gut bacteria and their derived microbial molecules involved in human insulin resistance.

Disentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota 
The findings emphasize the need to separate authentic disease signatures of the intestinal microbiome from those which are introduced by prescribed drugs.

Richness of human gut microbiome correlates with metabolic markers 
The study demonstrates how low gut microbial gene richness relates to insulin resistance, inflammation and increased body adiposity.